Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H49N7O9S |
Molecular Weight | 767.891 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC3=CC=CC=C3)C(N)=O
InChI
InChIKey=NEYNJQRKHLUJRU-DZUOILHNSA-N
InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
Pentagastrin (trade name Peptavlon) is a cholecystokinin type B (CCK(B)) receptor agonist, which was indicated as a diagnostic aid for evaluation of gastric acid secretory function. It was effective in testing for an acidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It was effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Pentagastrin was also indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor. Peptavlon was discontinued, Federal Register determined that product was not discontinued or withdrawn for safety or efficacy reasons. In addition was shown, that Pentagastrin may release adrenocorticotropin (ACTH) and cortisol through direct pharmacological action, perhaps enhanced on first exposure by psychologically mediated novelty effects. Novelty, per se, is not likely the primary mediator of the hypothalamic-pituitary-adrenal (HPA) response. This model may be useful for further study of cognitive-emotional modulators of HPA axis activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P32239 Gene ID: 887.0 Gene Symbol: CCKBR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12073167 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | PEPTAVLON Approved UseAnacidity (diagnosis)—Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis)—Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor Launch Date1.44028795E11 |
|||
Diagnostic | PEPTAVLON Approved UseAnacidity (diagnosis)—Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis)—Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor Launch Date1.44028795E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Vacuolar-type H+-ATPase-mediated proton transport in the rat parietal cell. | 2012 Mar |
|
Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. | 2012 Mar |
|
Can injection of pentagastrin stimulate the identification of metastases of medullary thyroid carcinoma by (18)F-FDG PET/CT? | 2012 May-Aug |
Sample Use Guides
The intravenous infusion dose has ranged from 0.1 to 12 ug (0.0001 to 0.012 mg) per kg of body weight per hour administered in a 0.9% sodium chloride injection.
As a subcutaneous injection for gastric function study with a dose of 6 ug (0.006 mg) per kg of body weight.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3707070
The centrifugal spreading of multicellular aggregates from a DMH induced colon adenocarcinoma cell line from rats was observed in vitro. Various concentrations of pentagastrin were added to the culture medium. Using 10 micrograms/ml of pentagastrin, the migration idex and the area covered by the cells were increased (P less than 0.01) while the cell density was not. Inhibition of cell division through addition of 5 fluoro-uracil to the culture medium abolished the stimulating effect of pentagastrin although the centrifugal migration was not suppressed by the antimetabolite. These data indicate that a supraphysiological concentration of pentagastrin can stimulate the spreading of colon cancer cell aggregates in vitro by enhanced proliferation.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV04CG04
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
||
|
FDA ORPHAN DRUG |
689719
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
||
|
FDA ORPHAN DRUG |
277509
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
||
|
WHO-ATC |
V04CG04
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
226-889-7
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
5534-95-2
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
9853654
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
EF0NX91490
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
3247
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
PENTAGASTRIN
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
CHEMBL1328
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
m8494
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | Merck Index | ||
|
C66340
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
DTXSID3048992
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
870
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
2387
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
SUB09678MIG
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
367746
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
DB00183
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
D010418
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
EF0NX91490
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
7993
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | RxNorm | ||
|
2088
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY | |||
|
100000082486
Created by
admin on Fri Dec 15 15:49:28 UTC 2023 , Edited by admin on Fri Dec 15 15:49:28 UTC 2023
|
PRIMARY |
ACTIVE MOIETY